Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pcmr.12321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.
JCO Precis Oncol
January 2025
Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Purpose: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP).
View Article and Find Full Text PDFSkin cancer treatment environment and survivorship resources among sexual and gender minority patients: results of the OUT National Cancer Survey.
Arch Dermatol Res
January 2025
Department of Dermatology, Emory University School of Medicine, Atlanta, GA, USA.
Sexual and gender minority (SGM) cancer survivors face unmet care needs in accessing cancer health information and social support despite high satisfaction with treatment. SGM patients often delay care due to concerns of discrimination in healthcare settings, though the care experiences of SGM skin cancer survivors are less known. SGM individuals, particularly sexual minority men, report higher skin cancer prevalence and related risk behaviors than heterosexual men.
View Article and Find Full Text PDFNivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma.
J Immunother Cancer
January 2025
Paris-Saclay University, Gif-sur-Yvette, Île-de-France, France
Background: Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not all patients benefit from them, and tools that could be used in the clinic to predict response to treatment represent an unmet need. Here we describe the development of a new population pharmacokinetic (PPK) model in patients treated with nivolumab in clinical trials.
View Article and Find Full Text PDFComparison of a Series of Ga-Labeled DOTA-LLP2A Conjugates for Positron Emission Tomography Imaging of Very Late Antigen-4 in Melanoma.
Mol Pharm
January 2025
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Melanoma, with its steadily rising global incidence, is characterized by high invasiveness, leading to poor prognosis in advanced stages. There remains an unmet clinical need for the development of radiolabeled PET imaging probes for the early diagnosis of melanoma. Integrin VLA-4, a key factor in melanoma metastasis, presents a promising protein target to address the specificity shortcomings of existing probes in melanoma imaging.
View Article and Find Full Text PDFTherapeutic Strategies in Neurocutaneous Melanocytosis.
Anticancer Res
December 2024
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.
Article Synopsis
- * The condition is usually fatal if symptoms appear, with a high chance of the brain lesions becoming malignant, especially in those with larger skin nevi.
- * Current treatments focus on palliative care and aim to manage symptoms, as there is no cure, highlighting the need for ongoing research to develop effective therapies and address this critical medical gap.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!